Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
Aditxt and Evofem file for stockholder approval to finalize their merger in Q4 2024. The acquisition will position Evofem as a wholly owned Aditxt subsidiary, enhancing their women’s health portfolio.